Trial Profile
A Pilot Phase II Study of Selinexor in Combination With Induction/Consolidation/Maintenance Therapy in Older AML Patients
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 08 May 2023
Price :
$35
*
At a glance
- Drugs Selinexor (Primary) ; Cytarabine; Daunorubicin
- Indications Acute myeloid leukaemia
- Focus Therapeutic Use
- 18 Feb 2022 Planned number of patients changed from 28 to 100.
- 18 Feb 2022 Planned End Date changed from 1 Jun 2022 to 1 Jun 2024.
- 18 Feb 2022 Planned primary completion date changed from 1 Jun 2022 to 1 Jun 2024.